Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

IMV

DB:5IV1
Snowflake Description

Reasonable growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5IV1
DB
CA$121M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • IMV has significant price volatility in the past 3 months.
5IV1 Share Price and Events
7 Day Returns
5.5%
DB:5IV1
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-52.5%
DB:5IV1
-13.5%
DE Biotechs
-20.9%
DE Market
5IV1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IMV (5IV1) 5.5% -46.5% -46.5% -52.5% -36.4% -19.9%
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 5IV1 underperformed the Biotechs industry which returned -13.5% over the past year.
  • 5IV1 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
5IV1
Industry
5yr Volatility vs Market

Value

 Is IMV undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of IMV to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for IMV.

DB:5IV1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:5IV1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 26.5%) (8.04%))
1.173
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.17
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.173 * 5.44%)
5.99%

Discounted Cash Flow Calculation for DB:5IV1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for IMV is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:5IV1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 5.99%)
2020 -32.10 Analyst x1 -30.29
2021 -38.11 Analyst x3 -33.92
2022 -45.88 Analyst x3 -38.53
2023 -22.08 Analyst x3 -17.50
2024 20.18 Analyst x3 15.08
2025 29.04 Est @ 43.95% 20.49
2026 37.95 Est @ 30.65% 25.25
2027 46.04 Est @ 21.34% 28.91
2028 52.87 Est @ 14.82% 31.32
2029 58.29 Est @ 10.26% 32.58
Present value of next 10 years cash flows CA$33.00
DB:5IV1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$58.29 × (1 + -0.39%) ÷ (5.99% – -0.39%)
CA$909.94
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$909.94 ÷ (1 + 5.99%)10
CA$508.55
DB:5IV1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$33.00 + CA$508.55
CA$541.55
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$541.55 / 51.03
CA$10.61
DB:5IV1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:5IV1 represents 0.64286x of TSX:IMV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.64286x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 10.61 x 0.64286
€6.82
Value per share (EUR) From above. €6.82
Current discount Discount to share price of €1.53
= -1 x (€1.53 - €6.82) / €6.82
77.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price IMV is available for.
Intrinsic value
>50%
Share price is €1.53 vs Future cash flow value of €6.82
Current Discount Checks
For IMV to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • IMV's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • IMV's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IMV's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IMV's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5IV1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.55
TSX:IMV Share Price ** TSX (2020-04-03) in CAD CA$2.38
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IMV.

DB:5IV1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:IMV Share Price ÷ EPS (both in CAD)

= 2.38 ÷ -0.55

-4.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IMV is loss making, we can't compare its value to the Europe Biotechs industry average.
  • IMV is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does IMV's expected growth come at a high price?
Raw Data
DB:5IV1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
17.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for IMV, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on IMV's assets?
Raw Data
DB:5IV1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.13
TSX:IMV Share Price * TSX (2020-04-03) in CAD CA$2.38
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:5IV1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:IMV Share Price ÷ Book Value per Share (both in CAD)

= 2.38 ÷ 0.13

18.69x

* Primary Listing of IMV.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IMV is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess IMV's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. IMV has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is IMV expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IMV expected to grow at an attractive rate?
  • IMV's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • IMV's earnings growth is expected to exceed the Germany market average.
  • IMV's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:5IV1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5IV1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 17.4%
DB:5IV1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 66.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5IV1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5IV1 Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 109 43 18 3
2023-12-31 4 -23 -38 3
2022-12-31 16 -43 -39 4
2021-12-31 2 -21 -35 5
2020-12-31 1 -32 -33 5
2020-04-06
DB:5IV1 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -27 -27
2019-09-30 0 -25 -27
2019-06-30 0 -25 -25
2019-03-31 0 -21 -25
2018-12-31 0 -17 -22
2018-09-30 0 -15 -19
2018-06-30 0 -12 -15
2018-03-31 0 -11 -13
2017-12-31 0 -9 -12
2017-09-30 0 -8 -11
2017-06-30 0 -7 -11
2017-03-31 0 -7 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IMV's earnings are expected to grow by 17.4% yearly, however this is not considered high growth (20% yearly).
  • IMV's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5IV1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from IMV Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5IV1 Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.23 2.00 -0.32 5.00
2023-12-31 -0.54 -0.25 -0.97 5.00
2022-12-31 -0.56 -0.36 -0.76 6.00
2021-12-31 -0.57 -0.36 -0.80 9.00
2020-12-31 -0.59 -0.46 -0.65 9.00
2020-04-06
DB:5IV1 Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.55
2019-09-30 -0.55
2019-06-30 -0.53
2019-03-31 -0.55
2018-12-31 -0.50
2018-09-30 -0.45
2018-06-30 -0.37
2018-03-31 -0.32
2017-12-31 -0.31
2017-09-30 -0.29
2017-06-30 -0.30
2017-03-31 -0.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IMV will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IMV's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IMV has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has IMV performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IMV's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IMV does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare IMV's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare IMV's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
IMV's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IMV Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5IV1 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.06 -27.37 10.14
2019-09-30 0.06 -26.57 9.12
2019-06-30 0.05 -24.67 8.84
2019-03-31 0.06 -24.81 9.29
2018-12-31 0.08 -21.94 9.24
2018-09-30 0.08 -19.18 8.91
2018-06-30 0.08 -15.32 7.74
2018-03-31 0.06 -12.73 6.41
2017-12-31 0.03 -12.03 6.42
2017-09-30 0.00 -10.84 5.39
2017-06-30 0.00 -10.61 5.33 -1.66
2017-03-31 0.06 -9.41 4.52 -0.77
2016-12-31 0.13 -8.90 4.24
2016-09-30 0.19 -7.60 3.83 1.20
2016-06-30 0.26 -7.71 3.55 3.98
2016-03-31 0.19 -8.86 4.08 4.55
2015-12-31 0.13 -8.77 3.93 4.57
2015-09-30 0.06 -8.36 3.81 4.26
2015-06-30 -7.62 3.55 4.01
2015-03-31 -6.39 2.94 3.42
2014-12-31 -6.57 3.05 3.54
2014-09-30 -5.36 2.07 3.35
2014-06-30 -5.40 2.49 3.00
2014-03-31 -5.04 2.84 2.73
2013-12-31 -4.68 2.69 2.54
2013-09-30 -5.57 3.29 2.85
2013-06-30 -5.96 2.98 3.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if IMV has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if IMV has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if IMV improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess IMV's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IMV has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is IMV's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IMV's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IMV is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IMV's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of IMV's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IMV Company Filings, last reported 3 months ago.

DB:5IV1 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 6.45 8.46 14.07
2019-09-30 14.64 8.41 21.37
2019-06-30 21.09 8.06 26.90
2019-03-31 25.81 8.53 34.21
2018-12-31 4.32 8.15 14.90
2018-09-30 11.11 7.49 20.27
2018-06-30 16.56 7.04 25.15
2018-03-31 16.66 6.79 24.02
2017-12-31 6.34 6.54 14.91
2017-09-30 10.38 6.41 16.60
2017-06-30 12.31 6.65 19.27
2017-03-31 5.40 6.39 11.77
2016-12-31 6.98 6.15 13.55
2016-09-30 2.99 5.01 7.91
2016-06-30 4.68 4.89 8.93
2016-03-31 -1.55 3.89 2.08
2015-12-31 0.07 3.78 3.84
2015-09-30 2.36 3.68 5.34
2015-06-30 4.01 3.59 6.93
2015-03-31 6.26 3.41 8.56
2014-12-31 7.81 3.19 10.66
2014-09-30 9.61 3.06 12.50
2014-06-30 0.09 2.19 1.71
2014-03-31 1.17 1.36 2.05
2013-12-31 2.59 1.33 3.54
2013-09-30 -0.69 1.81 1.14
2013-06-30 0.93 0.58 0.89
  • IMV's level of debt (131.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (41% vs 131.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • IMV has less than a year of cash runway based on current free cash flow.
  • IMV has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.9% each year.
X
Financial health checks
We assess IMV's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IMV has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is IMV's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IMV dividends.
If you bought €2,000 of IMV shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IMV's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IMV's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5IV1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5IV1 Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IMV has not reported any payouts.
  • Unable to verify if IMV's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IMV's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IMV has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IMV's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IMV afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IMV has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of IMV's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fred Ors
COMPENSATION CA$1,335,893
AGE 45
TENURE AS CEO 4 years
CEO Bio

Mr. Frederic Ors, also known as Fred, B.Sc., M.A., has been Chief Executive Officer of IMV Inc. since April 14, 2016 and served as its President. Mr. Ors served as Acting Chief Executive Officer of IMV Inc. from March 2016 to April 2016. He served as Chief Business Officer at IMV Inc. from April 27, 2015 to April 2016. He served as Vice President of Medicago Inc. He served as Vice President of Business Development for Medicago Inc. He joined Medicago in 2001 as Project Manager in Technology Transfer, following that he was Business Development Director and was Vice-President of Business Development. In addition to business development activities, Mr. Ors is also responsible for Medicago’s intellectual property and licensing activities. He was responsible for industry relations during four years at one of the largest science and medical universities in Paris, France. He served as Manager of Intellectual Property and Licensing for Paris Diderot University. He has over 13 years of experience in business development, intellectual property and licensing in biotechnology. He has extensive experience in management, financing and commercialization in the field of biotechnology. He has been a Director of IMV Inc. since April 14, 2016. Mr. Ors holds a B.Sc. degree in biology and a Master degree in innovation’s sciences and techniques, option biology from Angers University (France).

CEO Compensation
  • Fred's compensation has increased whilst company is loss making.
  • Fred's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the IMV management team in years:

2.3
Average Tenure
  • The tenure for the IMV management team is about average.
Management Team

Fred Ors

TITLE
CEO & Director
COMPENSATION
CA$1M
AGE
45
TENURE
4 yrs

Pierre Labbé

TITLE
Chief Financial Officer
COMPENSATION
CA$883K
AGE
54
TENURE
3.2 yrs

Joe Sullivan

TITLE
Senior Vice President of Business Development
COMPENSATION
CA$744K
TENURE
2.3 yrs

Marc Jasmin

TITLE
Senior Director of Investor Relations & Communications
TENURE
1.3 yrs

Joanne Schindler

TITLE
Chief Medical Officer
TENURE
0.4 yrs

Marianne Stanford

TITLE
Vice President of Research & Development
Board of Directors Tenure

Average tenure and age of the IMV board of directors in years:

4
Average Tenure
67
Average Age
  • The tenure for the IMV board of directors is about average.
Board of Directors

Andy Sheldon

TITLE
Independent Chairman of the Board
COMPENSATION
CA$179K
TENURE
4 yrs

Fred Ors

TITLE
CEO & Director
COMPENSATION
CA$1M
AGE
45
TENURE
4 yrs

Jim Hall

TITLE
Independent Director
COMPENSATION
CA$113K
AGE
72
TENURE
10.2 yrs

Wayne Pisano

TITLE
Independent Director
COMPENSATION
CA$118K
AGE
64
TENURE
8.5 yrs

Shermaine Tilley

TITLE
Independent Director
AGE
67
TENURE
3.8 yrs

Julia P. Gregory

TITLE
Independent Director
COMPENSATION
CA$162K
AGE
67
TENURE
1.8 yrs

David Spaner

TITLE
Member of Scientific & Clinical Advisory Committee

Kunle Odunsi

TITLE
Member of Scientific & Clinical Advisory Committee

Brad Nelson

TITLE
Member of Scientific & Clinical Advisory Committee

James Johnston

TITLE
Member of Scientific & Clinical Advisory Committee
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Oct 19 Buy Frederic Ors Individual 04. Oct 19 04. Oct 19 5,000 €2.59 €12,955
04. Oct 19 Buy Andrew Sheldon Individual 03. Oct 19 03. Oct 19 2,500 €2.39 €5,952
21. Jun 19 Buy Frederic Ors Individual 21. Jun 19 21. Jun 19 5,000 €2.70 €13,520
21. Jun 19 Buy Pierre Labbé Individual 21. Jun 19 21. Jun 19 2,500 €2.72 €6,801
21. Jun 19 Buy Andrew Sheldon Individual 21. Jun 19 21. Jun 19 5,000 €2.84 €14,203
18. Jun 19 Buy Joseph Sullivan Individual 14. Jun 19 14. Jun 19 1,000 €3.12 €3,097
14. Jun 19 Buy Joseph Sullivan Individual 13. Jun 19 13. Jun 19 1,000 €3.41 €3,415
01. May 19 Buy Andrew Sheldon Individual 30. Apr 19 30. Apr 19 2,500 €3.30 €8,251
30. Apr 19 Buy Frederic Ors Individual 26. Apr 19 26. Apr 19 3,500 €2.96 €10,367
29. Apr 19 Buy Pierre Labbé Individual 29. Apr 19 29. Apr 19 5,000 €3.28 €15,767
26. Apr 19 Buy Pierre Labbé Individual 26. Apr 19 26. Apr 19 5,000 €2.94 €14,447
25. Apr 19 Buy Pierre Labbé Individual 25. Apr 19 25. Apr 19 3,000 €2.73 €8,183
18. Apr 19 Buy Andrew Sheldon Individual 17. Apr 19 17. Apr 19 2,000 €3.07 €6,140
16. Apr 19 Buy Andrew Sheldon Individual 15. Apr 19 15. Apr 19 4,600 €2.86 €13,172
X
Management checks
We assess IMV's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IMV has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Details
Name: IMV Inc.
5IV1
Exchange: DB
Founded: 2000
CA$79,651,086
51,028,180
Website: http://imv-inc.com
Address: IMV Inc.
130 Eileen Stubbs Avenue,
Suite 19,
Dartmouth,
Nova Scotia, B3B 2C4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX IMV Common Shares The Toronto Stock Exchange CA CAD 02. Oct 2009
NasdaqCM IMV Common Shares Nasdaq Capital Market US USD 02. Oct 2009
DB 5IV1 Common Shares Deutsche Boerse AG DE EUR 02. Oct 2009
Number of employees
Current staff
Staff numbers
62
IMV employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 04:09
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.